红色诺卡氏菌细胞壁骨架对70例肺癌恶性胸腔积液患者近远期预后的影响

Nocardia rubra cell wall skeleton for treatment of malignant pleural effusions caused by lung cancer: efficacy and short-term prognosis in 70 patients

目的:观察红色诺卡氏菌细胞壁骨架对肺癌恶性胸腔积液患者的临床疗效以及预后影响。方法:选取2015年6月-2018年9月期间福建省第二人民医院收治的70例肺癌恶性胸腔积液患者为研究对象。将患者按随机数表法分为观察组和对照组各35例,对照组给予恶性胸腔积液胸水持续引流,观察组在此基础上联合红色诺卡氏菌细胞壁骨架治疗。观察比较两组患者的临床疗效、免疫功能、不良反应以及预后影响。结果:观察组临床总有效率,免疫功能(CD3、CD8及CD4阳性T细胞百分比)显著优于对照组(P<0.05);观察组中位生存期长于对照组(P<0.05);且两组不良反应发生率无统计学意义(P<0. 05)。结论:红色诺卡氏菌细胞壁骨架对肺癌恶性胸腔积液患者有较好的临床疗效,能提高患者免疫功能和生存率,且毒副作用轻,值得推广。

Objective:To investigate the clinical efficacy and prognosis in patients with malignant pleural effusion caused by lung cancer treated with Nocardia rubra cell wall skeleton(N-CWS).Methods:Seventy patients with malignant pleural effusions caused by lung cancer admitted to the Second People’s Hospital of Fujian Province between June 2015 and September 1818 were enrolled.The patients were divided into the study group and control group according to random number table method.The control group was given sustained drainage of the malignant pleural effusions;in addition to this,the study group was given N-CWS.The clinical efficacy,immune function,adverse reactions and prognosis of the two groups were compared.Results:The total effective rate and immune function(percentage counts of CD3,CD8 and CD4 positive T cells)in the study group were significantly favorable than those in the control group(P<0.05).The median survival length of the study group was longer than that of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P<0.05).Conclusion:N-CWS offers better clinical efficacy to patients with malignant pleural effusion caused by lung cancer by improving the immune function and survival rate with milder adverse and toxic effects,and therefore is worthwhile for widespread use in clinical setting.